Trop-2 Targeted PET Probes in Advanced TNBC

Inclusion Criteria

• •1. Aged 18 - 75 years, male or female, with an ECOG score ≥ 2.
• •2. Blood routine, liver and kidney functions meet the following standards:
• •* Blood routine: Total white blood cell count (WBC) ≥ 3.0×10⁹/L or neutrophil count (Neu) ≥ 1.5×10⁹/L, platelet count (PLT) ≥ 80×10⁹/L, hemoglobin (Hb) ≥ 80 g/L.
• •* Liver and kidney functions: Total bilirubin (T - Bil) ≤ 1.5×ULN (upper limit of normal value), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN or ≤ 5×ULN (in case of liver metastasis), serum creatinine (SCr) ≤ 1.5×ULN.
• •3. Subjects with advanced triple - negative breast cancer previously diagnosed by histopathological diagnosis and imaging evaluation.
• •4. Expected survival time ≥ 12 weeks.
• •5. Clinicians assess that TROP - 2 ADC is an appropriate treatment plan for the subject at present.
• •6. There is at least one measurable target lesion in accordance with the RECIST 1.1 standard.
• •7. Subjects for whom clinicians recommend PET/CT examination for breast tumor diagnosis and staging.
• •8. Women of childbearing age (18 - 60 years old) must undergo a pregnancy test within 7 days before the start of the examination and the result is negative; Male and female subjects with fertility must agree to use effective contraceptive measures to ensure no pregnancy during the study period and within 3 months after the examination.
• •9. The subject can fully understand and voluntarily participate in this experiment, sign the informed consent form, and have good follow - up compliance.